Polymeric lamellar substrate particles for intranasal vaccination.
In recent years, several strategies have been under investigation to achieve safe and effective immunisation, in terms of new antigens, adjuvants and routes of vaccination. The latter include mucosal sites such as oral, rectal, vaginal and nasal. Biodegradable microparticles produced from polymers such as poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) containing encapsulated vaccine antigens have been extensively studied for immunisation. These microparticles allow controlled release of vaccines with the aim to develop as single dose vaccines. However there are concerns regarding the integrity and immunogenicity of the antigen during the encapsulation process when the antigen is exposed to organic solvents, high shear stresses and the exposure of antigen to low pH which is caused by polymer degradation. Polymeric lamellar substrate particles (PLSP) produced by simple precipitation of PLA, form a novel polymeric system for the adsorption of antigens. This procedure avoids pH changes, exposure to organic solvents and hence allows the integrity of the antigen to be retained. The aim of this article is to discuss the factors affecting the characteristics of PLSP and adsorption of antigens onto PLSP and consider their potential as adjuvants for the nasal delivery of protein, peptide or viral vaccines.
Jabbal-Gill
I
I
West Pharmaceutical Services Drug Delivery and Clinical Research Centre Ltd., Albert Einstein Centre, Nottingham Science & Technology Park, University Boulevard, NG7 2TN, Nottingham, UK.
Lin
W
W
Kistner
O
O
Davis
S S
SS
Illum
L
L
D000281:Administration, Intranasal; D000327:Adsorption; D000818:Animals; D006801:Humans; D018928:Immunity, Mucosal; D011091:Polyesters / Q000008:administration & dosage* / Q000737:chemistry; D014611:Vaccination; D014612:Vaccines / Q000008:administration & dosage*
D011091:Polyesters; D014612:Vaccines; C033616:poly(lactide)